106
Participants
Start Date
April 30, 2024
Primary Completion Date
July 31, 2024
Study Completion Date
December 31, 2024
Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Bolus administration of 2 mL undiluted Lumason®, to be administered in 20 seconds
Lumason
Continuous infusion of 8 mL of diluted Lumason® (4 mL of Lumason® diluted in 4 mL of saline) at a rate of 1.0 mL/min
Piedmont Heart Institute, Atlanta
Oregon Health and Sciences University, Portland
Beth Israel Deaconess Medical Center, Boston
Lead Sponsor
Bracco Diagnostics, Inc
INDUSTRY